Matthew D. Hellmann
YOU?
Author Swipe
View article: Supplementary Figure 9 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Figure 9 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer Open
Supplementary Figure 9. Effect of ICI treatment duration on post-discontinuation survival outcomes using a restricted cubic spline model.
View article: Supplementary Figure 3 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Figure 3 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer Open
Supplementary Figure 3. Post-discontinuation survival outcomes according to age, histology, and best overall response.
View article: Supplementary Figure 1 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Figure 1 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer Open
Supplementary Figure 1. Study consort diagram.
View article: Data from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer
Data from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer Open
Purpose:Among patients with advanced non–small cell lung cancer (NSCLC) who discontinue immune checkpoint inhibitors (ICI) because of immune-related adverse events (irAE), post-discontinuation clinical outcomes and factors associated with …
View article: Supplementary Figure 4 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Figure 4 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer Open
Supplementary Figure 4. Post-discontinuation survival outcomes according to best overall response using a modified SD.
View article: Supplementary Tables 1-18 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Tables 1-18 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer Open
Supplementary Tables 1-18
View article: Supplementary Figure 5 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Figure 5 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer Open
Supplementary Figure 5. Post-discontinuation survival outcomes according to type of immune-related adverse events.
View article: Supplementary Figure 7 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Figure 7 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer Open
Supplementary Figure 7. Post-discontinuation survival outcomes according to PD-L1 TPS and TMB.
View article: Supplementary Figure 6 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Figure 6 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer Open
Supplementary Figure 6. Post-discontinuation survival outcomes according to type of therapy used for immune-related adverse events management.
View article: Supplementary Figure 2 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Figure 2 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer Open
Supplementary Figure 2. Timing of ICI discontinuation due to immune-related adverse events.
View article: Supplementary Figure 8 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Figure 8 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer Open
Supplementary Figure 8. Post-discontinuation survival outcomes according to ICI treatment duration before discontinuation.
View article: Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer
Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer Open
Despite the established use of immune checkpoint inhibitors (ICIs) to treat non-small cell lung cancer (NSCLC), only a subset of patients benefit from treatment and ∼50% of patients whose tumors respond eventually develop acquired resistan…
View article: Supplemental Fig. 1 from The GENIE BPC NSCLC cohort: a real-world repository integrating standardized clinical and genomic data for 1,846 patients with non-small cell lung cancer
Supplemental Fig. 1 from The GENIE BPC NSCLC cohort: a real-world repository integrating standardized clinical and genomic data for 1,846 patients with non-small cell lung cancer Open
Supplemental Figure 1: OS and PFS for KRAS-mutated NSCLC treated with first-line platinum-based chemotherapy.
View article: Supplementary Figure S2 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer
Supplementary Figure S2 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer Open
Kaplan-Meier curve of progression-free survival (PFS) among patients with long-term response (LTR) in the combined cohort.
View article: Supplementary Figure S11 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer
Supplementary Figure S11 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer Open
Genomic features of patients with long-term response (LTR) compared to short term response (STR), non-LTR, and progressive disease (PD) among patients with TMB z-score < 0.
View article: Supplementary Table S3 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer
Supplementary Table S3 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer Open
Frequencies of alterations in individual genes among squamous and non-squamous patient groups.
View article: Supplemental Table 4 from The GENIE BPC NSCLC cohort: a real-world repository integrating standardized clinical and genomic data for 1,846 patients with non-small cell lung cancer
Supplemental Table 4 from The GENIE BPC NSCLC cohort: a real-world repository integrating standardized clinical and genomic data for 1,846 patients with non-small cell lung cancer Open
Supplemental Table 4
View article: Supplementary Figure S14 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer
Supplementary Figure S14 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer Open
Whole exome sequencing (WES) features of patients with long-term response (LTR), short-term response (STR), and progressive disease (PD).
View article: Supplementary Figure S7 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer
Supplementary Figure S7 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer Open
Univariable and multivariable analyses of association of clinical characteristics with patients achieving complete response (CR) compared to patients not achieving complete response (non-CR).
View article: Supplemental Table 3 from The GENIE BPC NSCLC cohort: a real-world repository integrating standardized clinical and genomic data for 1,846 patients with non-small cell lung cancer
Supplemental Table 3 from The GENIE BPC NSCLC cohort: a real-world repository integrating standardized clinical and genomic data for 1,846 patients with non-small cell lung cancer Open
Supplemental Table 3
View article: Supplemental Fig. 2 from The GENIE BPC NSCLC cohort: a real-world repository integrating standardized clinical and genomic data for 1,846 patients with non-small cell lung cancer
Supplemental Fig. 2 from The GENIE BPC NSCLC cohort: a real-world repository integrating standardized clinical and genomic data for 1,846 patients with non-small cell lung cancer Open
Supplemental Figure 2: OS and PFS for patients with NSCLC treated with first-line platinum-based chemotherapy.
View article: Supplementary Figure S1 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer
Supplementary Figure S1 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer Open
Frequency of patients with long-term response (LTR), short-term response (STR), and progressive disease (PD) from individual clinical sites.
View article: Supplemental Fig. 3 from The GENIE BPC NSCLC cohort: a real-world repository integrating standardized clinical and genomic data for 1,846 patients with non-small cell lung cancer
Supplemental Fig. 3 from The GENIE BPC NSCLC cohort: a real-world repository integrating standardized clinical and genomic data for 1,846 patients with non-small cell lung cancer Open
Supplemental Figure 3: PFS estimates for patients with NSCLC treated with standard first- and second-line therapies.
View article: Supplementary Figure S4 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer
Supplementary Figure S4 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer Open
Time on treatment among patients with long-term response (LTR).
View article: Supplementary Figure S15 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer
Supplementary Figure S15 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer Open
Fraction of subclonal non-synonymous mutations among patients with long-term response (LTR), short-term response (STR), and progressive disease (PD).
View article: Supplemental Table 3 from The GENIE BPC NSCLC cohort: a real-world repository integrating standardized clinical and genomic data for 1,846 patients with non-small cell lung cancer
Supplemental Table 3 from The GENIE BPC NSCLC cohort: a real-world repository integrating standardized clinical and genomic data for 1,846 patients with non-small cell lung cancer Open
Supplemental Table 3
View article: Supplemental Table 4 from The GENIE BPC NSCLC cohort: a real-world repository integrating standardized clinical and genomic data for 1,846 patients with non-small cell lung cancer
Supplemental Table 4 from The GENIE BPC NSCLC cohort: a real-world repository integrating standardized clinical and genomic data for 1,846 patients with non-small cell lung cancer Open
Supplemental Table 4
View article: Supplementary Table S4 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer
Supplementary Table S4 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer Open
Frequencies of alterations in individual genes among non-squamous patient groups stratified by TMB z-score.
View article: Supplementary Figure S10 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer
Supplementary Figure S10 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer Open
Genomic features of patients with long-term response (LTR) compared to non-LTR and progressive disease (PD).
View article: Supplementary Figure S5 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer
Supplementary Figure S5 from Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer Open
Kaplan-Meier curves of (A) overall survival (OS) and (B) progression-free survival (PFS) among patients with complete response (CR) in the combined cohort.